Change in hemostatic markers after recombinant tissue-type plasminogen activator is not associated with the chance of recanalization.
We evaluated the association between recombinant tissue-type plasminogen activator recanalization and change in hemostatic markers. We studied 40 patients. Recanalization was measured with transcranial Doppler. We evaluated the change in markers of coagulation (fibrinogen) and fibrinolysis (thrombin activatable fibrinolysis inhibitor and alpha(2)-antiplasmin) in patients with ischemic stroke treated with recombinant tissue-type plasminogen activator. Samples were obtained before and 90 minutes after recombinant tissue-type plasminogen activator infusion. The analyses (2-way analysis of variance) showed that the change in the value of each marker did not depend on the vascular patency status. From a practical point of view, the measurement of these hemostatic markers is probably not useful for predicting recanalization.